Physician profile
Michael Grant
NPI 1154851467
$9,494.38
in general payments reported to CMS, 2019-2025
26 companies · $2,477 in 2025
The $2,477 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $662 · 2023: $3,165 · 2024: $3,191 · 2025: $2,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,434 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,433.81 |
| Education | $398.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,902.52 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $1,231.97 | 2022-2025 | |
| Janssen Biotech, INC. | $1,138.99 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $660.73 | 2022-2025 | Cimzia, Bimzelx, Rystiggo |
| Glaxosmithkline, LLC. | $654.93 | 2022-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $647.62 | 2022-2025 | Saphnelo, Evusheld |
| Novartis Pharmaceuticals Corporation | $640.49 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $382.10 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $350.56 | 2022-2025 | Acthar |
| Organon LLC | $343.69 | 2022-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $230.90 | 2023-2025 | Tymlos |
| Horizon Therapeutics Plc | $217.12 | 2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $208.32 | 2023-2025 | Idacio |
| Lilly USA, LLC | $192.57 | 2022-2025 | Taltz, Olumiant |
| Genentech USA, INC. | $180.87 | 2022-2025 | Actemra, Rituxan, Ocrevus |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $129.32 | 2024-2025 | General - Pain Management, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.53 | 2023-2024 | Cyltezo |
| Pfizer INC. | $57.07 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $53.74 | 2023-2025 | Opsumit, Uptravi |
| Globus Medical, INC. | $50.65 | 2025 | Senza |
| E.R. Squibb & Sons, L.L.C. | $33.09 | 2025 | Orencia |
| Sobi, INC | $28.36 | 2024-2025 | |
| Genzyme Corporation | $21.66 | 2024 | |
| Sandoz INC. | $20.00 | 2024 | Hyrimoz |
| Argenx US, INC. | $17.57 | 2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $13.01 | 2023 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.